KR102640722B1 - 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물 - Google Patents

클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102640722B1
KR102640722B1 KR1020197030108A KR20197030108A KR102640722B1 KR 102640722 B1 KR102640722 B1 KR 102640722B1 KR 1020197030108 A KR1020197030108 A KR 1020197030108A KR 20197030108 A KR20197030108 A KR 20197030108A KR 102640722 B1 KR102640722 B1 KR 102640722B1
Authority
KR
South Korea
Prior art keywords
asn
gly
ile
asp
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030108A
Other languages
English (en)
Korean (ko)
Other versions
KR20190125470A (ko
Inventor
징-후이 티엔
예 류
게일 스미스
그레고리 글렌
데이비드 플라이어
Original Assignee
노바백스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바백스, 인코포레이티드 filed Critical 노바백스, 인코포레이티드
Publication of KR20190125470A publication Critical patent/KR20190125470A/ko
Application granted granted Critical
Publication of KR102640722B1 publication Critical patent/KR102640722B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197030108A 2017-03-15 2018-03-15 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물 Active KR102640722B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471636P 2017-03-15 2017-03-15
US62/471,636 2017-03-15
US201762474434P 2017-03-21 2017-03-21
US62/474,434 2017-03-21
PCT/US2018/022597 WO2018170238A2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Publications (2)

Publication Number Publication Date
KR20190125470A KR20190125470A (ko) 2019-11-06
KR102640722B1 true KR102640722B1 (ko) 2024-02-26

Family

ID=63523217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030108A Active KR102640722B1 (ko) 2017-03-15 2018-03-15 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물

Country Status (12)

Country Link
US (2) US11123419B2 (https=)
EP (1) EP3595709A4 (https=)
JP (2) JP7149285B2 (https=)
KR (1) KR102640722B1 (https=)
CN (1) CN110691609B (https=)
AU (1) AU2018236352B2 (https=)
BR (1) BR112019019117A2 (https=)
CA (1) CA3056090A1 (https=)
IL (1) IL269258B2 (https=)
MX (1) MX2019010948A (https=)
SG (1) SG11201908376UA (https=)
WO (1) WO2018170238A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
MX2019010948A (es) * 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011711A1 (en) * 1997-09-04 1999-03-11 Eastman Chemical Company Thermoplastic polyurethane additives for enhancing solid state polymerization rates
WO2015197737A1 (en) * 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20130039973A1 (en) * 2011-08-03 2013-02-14 Henry J. Smith Viral Immunogenic Compositions
RU2014117068A (ru) 2011-09-30 2015-11-10 Новавакс, Инк. Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CN105451762A (zh) 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
WO2015063647A1 (en) * 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
CN106220737B (zh) * 2016-07-21 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白及其在治疗艰难梭菌相关疾病中的应用
MX2019010948A (es) 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011711A1 (en) * 1997-09-04 1999-03-11 Eastman Chemical Company Thermoplastic polyurethane additives for enhancing solid state polymerization rates
WO2015197737A1 (en) * 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition

Also Published As

Publication number Publication date
CA3056090A1 (en) 2018-09-20
KR20190125470A (ko) 2019-11-06
RU2019132111A3 (https=) 2021-06-29
EP3595709A2 (en) 2020-01-22
SG11201908376UA (en) 2019-10-30
US11938179B2 (en) 2024-03-26
JP2020509770A (ja) 2020-04-02
WO2018170238A3 (en) 2018-10-18
IL269258B2 (en) 2023-09-01
US11123419B2 (en) 2021-09-21
US20200085934A1 (en) 2020-03-19
BR112019019117A2 (pt) 2020-05-05
AU2018236352A1 (en) 2019-10-03
JP2022179543A (ja) 2022-12-02
JP7397145B2 (ja) 2023-12-12
RU2019132111A (ru) 2021-04-15
CN110691609B (zh) 2024-04-19
EP3595709A4 (en) 2020-12-23
MX2019010948A (es) 2020-01-09
US20220211834A1 (en) 2022-07-07
IL269258B1 (en) 2023-05-01
JP7149285B2 (ja) 2022-10-06
CN110691609A (zh) 2020-01-14
WO2018170238A2 (en) 2018-09-20
AU2018236352B2 (en) 2024-04-04
IL269258A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US11938179B2 (en) Methods and compositions for inducing immune responses against Clostridium difficile
US12195501B2 (en) Mutant fragments of OspA and methods and uses relating thereto
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
JP2013520487A (ja) 免疫原性タンパク質および組成物
JP2012532626A (ja) 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
CN104560780B (zh) 产气荚膜梭菌ε毒素减毒突变体及其应用
CN117003885B (zh) H5n8禽流感广谱性疫苗的开发及其应用
RU2781057C2 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
RU2781057C9 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
EP1131338B1 (en) Method for the production of purified invasin protein and use thereof
US9493518B2 (en) Compositions and methods for treating clostridium difficile-associated diseases
US20210220462A1 (en) Immunogenic proteins and compositions
HK40035688A (en) Mutant fragments of ospa and methods and uses relating thereto
HK1257893B (en) Mutant fragments of ospa and methods and uses relating thereto
TW201722983A (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000